Cognition Therapeutics, Inc. is a clinical stage pharmaceutical company targeting neurodegenerative disorders. Our lead molecule CT1812 is currently in the clinic for Alzheimer’s disease modification. Located in Pittsburgh’s historic South Side, we are seeking highly motivated individuals to work in a dynamic company environment.
Research Scientist, Neurobiology
The candidate will be a key contributor in a scientific research team developing cutting-edge cell-based assays. Responsibilities include assay development, execution and statistical analysis of studies of first-in-class compound mechanism of action using primary neuronal cultures.
The candidate will work with others in a team-based environment and make formal presentations of experimental results to the company.
Ph.D. in neurobiology, industry experience a plus
Background in learning and memory biology, neurodegenerative disease biology
Technical expertise in primary neuronal cultures, immunohistochemistry, westerns, ELISAs, FRET-based assays, microscopy, automated imaging with Cellomics platform.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally avail...able small molecule that is currently in clinical trials in patients with mild-to-moderate Alzheimer’s disease. This highly brain penetrant compound targets the sigma-2/PGRMC1 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Additional information about Cognition may be found online at http://www.cogrx.com.